Caris Life Sciences landed more than $800 million in funding.
The Irving company, which is bringing a multi-pronged approach to helping treat cancers, has raised an $830 million growth equity round at a post-money valuation of $7.83 billion, it said in a statement Tuesday.
Caris has now raised roughly $1.3 billion in external financing since 2018. In October, the company announced it had raised $310 million in growth capital, including $235 million in equity financing.
The company has been getting more attention as demand for personalized cancer care expands. Caris helps patients and physicians seeking to better understand their specific cancers to develop customized treatment plans that assist with outcomes.
This financing provides strategic capital for ongoing commercial expansion along with investment toward delivering a liquid biopsy platform, a non-invasive alternative in some cases.
Presented by Dallas Business Journal